Skip to content

Insider · CIK 0001771498

Jacqueline Elizabeth Shea

ceoofficerdirector

Files at INO (INOVIO PHARMACEUTICALS, INC.). First filing -, latest -.

In brief

Jacqueline Elizabeth Shea files SEC Form 4 as CEO and director at INO (INOVIO PHARMACEUTICALS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.

A track record needs three past buys with six months of prices behind them; Jacqueline Elizabeth Shea has 0, so none is measured yet.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold

Signals

This insider’s open-market buys and sells, scored.

No scored open-market trades yet.

Transactions

Every row this insider has filed, 32 in all, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
May 20, 2026INO
INOVIO PHARMACEUTICALS, INC.
MOption exercise
Common Stock
+28,296--123,327May 21, 2026
May 20, 2026INO
INOVIO PHARMACEUTICALS, INC.
FTax withholding
Common Stock
-12,306$1.23$15k111,021May 21, 2026
May 20, 2026INO
INOVIO PHARMACEUTICALS, INC.
MOption exercise
Restricted Stock Unitderivative
-28,296$0.00$056,592May 21, 2026
May 20, 2026INO
INOVIO PHARMACEUTICALS, INC.
AGrant or award
Common Stock Optionderivative
+123,760$0.00$0123,760May 21, 2026
May 20, 2026INO
INOVIO PHARMACEUTICALS, INC.
AGrant or award
Restricted Stock Unitderivative
+100,240$0.00$0100,240May 21, 2026
May 15, 2026INO
INOVIO PHARMACEUTICALS, INC.
MOption exercise
Common Stock
+17,744--102,748May 18, 2026
May 15, 2026INO
INOVIO PHARMACEUTICALS, INC.
FTax withholding
Common Stock
-7,717$1.30$10k95,031May 18, 2026
May 15, 2026INO
INOVIO PHARMACEUTICALS, INC.
MOption exercise
Restricted Stock Unitderivative
-17,744$0.00$00May 18, 2026
Mar 4, 2026INO
INOVIO PHARMACEUTICALS, INC.
AGrant or award
Common Stock Optionderivative
+97,240$0.00$097,240Mar 5, 2026
Mar 4, 2026INO
INOVIO PHARMACEUTICALS, INC.
AGrant or award
Restricted Stock Unitderivative
+78,760$0.00$078,760Mar 5, 2026
Feb 26, 2026INO
INOVIO PHARMACEUTICALS, INC.
MOption exercise
Common Stock
+18,632--78,317Feb 27, 2026
Feb 26, 2026INO
INOVIO PHARMACEUTICALS, INC.
FTax withholding
Common Stock
-8,057$1.79$14k70,260Feb 27, 2026
Feb 26, 2026INO
INOVIO PHARMACEUTICALS, INC.
MOption exercise
Common Stock
+28,401--98,661Feb 27, 2026
Feb 26, 2026INO
INOVIO PHARMACEUTICALS, INC.
FTax withholding
Common Stock
-13,657$1.79$24k85,004Feb 27, 2026
Feb 26, 2026INO
INOVIO PHARMACEUTICALS, INC.
MOption exercise
Restricted Stock Unitderivative
-18,632$0.00$018,631Feb 27, 2026
Feb 26, 2026INO
INOVIO PHARMACEUTICALS, INC.
MOption exercise
Restricted Stock Unitderivative
-28,401$0.00$056,800Feb 27, 2026
May 20, 2025INO
INOVIO PHARMACEUTICALS, INC.
AGrant or award
Restricted Stock Unitderivative
+84,888$0.00$084,888May 21, 2025
May 20, 2025INO
INOVIO PHARMACEUTICALS, INC.
AGrant or award
Common Stock Optionderivative
+105,262$0.00$0105,262May 21, 2025
May 15, 2025INO
INOVIO PHARMACEUTICALS, INC.
MOption exercise
Common Stock
+17,744--67,402May 16, 2025
May 15, 2025INO
INOVIO PHARMACEUTICALS, INC.
FTax withholding
Common Stock
-7,717$1.95$15k59,685May 16, 2025
May 15, 2025INO
INOVIO PHARMACEUTICALS, INC.
MOption exercise
Restricted Stock Unitderivative
-17,744$0.00$017,744May 16, 2025
May 10, 2025INO
INOVIO PHARMACEUTICALS, INC.
MOption exercise
Common Stock
+5,500--52,050May 12, 2025
May 10, 2025INO
INOVIO PHARMACEUTICALS, INC.
FTax withholding
Common Stock
-2,392$1.80$4,30649,658May 12, 2025
May 10, 2025INO
INOVIO PHARMACEUTICALS, INC.
MOption exercise
Restricted Stock Unitderivative
-5,500$0.00$00May 12, 2025
Feb 26, 2025INO
INOVIO PHARMACEUTICALS, INC.
MOption exercise
Common Stock
+5,852--39,499Feb 28, 2025
Feb 26, 2025INO
INOVIO PHARMACEUTICALS, INC.
FTax withholding
Common Stock
-2,493$1.98$4,93637,006Feb 28, 2025
Feb 26, 2025INO
INOVIO PHARMACEUTICALS, INC.
MOption exercise
Common Stock
+18,632--55,638Feb 28, 2025
Feb 26, 2025INO
INOVIO PHARMACEUTICALS, INC.
FTax withholding
Common Stock
-9,088$1.98$18k46,550Feb 28, 2025
Feb 26, 2025INO
INOVIO PHARMACEUTICALS, INC.
MOption exercise
Restricted Stock Unitderivative
-5,852$0.00$00Feb 28, 2025
Feb 26, 2025INO
INOVIO PHARMACEUTICALS, INC.
MOption exercise
Restricted Stock Unitderivative
-18,632$0.00$037,263Feb 28, 2025
Feb 27, 2025INO
INOVIO PHARMACEUTICALS, INC.
AGrant or award
Common Stock Optionderivative
+105,649$0.00$0105,649Feb 28, 2025
Feb 27, 2025INO
INOVIO PHARMACEUTICALS, INC.
AGrant or award
Restricted Stock Unitderivative
+85,201$0.00$085,201Feb 28, 2025

Questions about Jacqueline Elizabeth Shea

Answered from the filings on this page, as of the latest one.

Is Jacqueline Elizabeth Shea buying or selling?

Jacqueline Elizabeth Shea has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.

How did Jacqueline Elizabeth Shea's past buys perform?

Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jacqueline Elizabeth Shea has 0.

Where does Jacqueline Elizabeth Shea file Form 4?

Jacqueline Elizabeth Shea has filed Form 4 at INO (INOVIO PHARMACEUTICALS, INC.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Jacqueline Elizabeth Shea: insider trades and track record | InsiderTell